Pancreatic cancer radiation gets a boost: safety trial tests higher doses

NCT ID NCT02454140

Completed Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed phase I trial tested whether higher doses of a precise type of radiation called stereotactic body radiotherapy (SBRT) are safe for people with pancreatic cancer. Thirty patients with inoperable or locally advanced pancreatic cancer received five targeted radiation sessions. The main goal was to find the highest dose that doesn't cause severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiotherapy (SBRT) - a precise, high-dose radiation treatment
What this could lead to: If successful, this could help determine a safer, more effective radiation dose for treating pancreatic cancer, potentially improving local tumor control.
What could go wrong: This is a small, early-phase trial focused on safety, not effectiveness. The higher doses may cause more side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

UCSD Moores Cancer Center

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.